Compare YPF & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | YPF | NVO |
|---|---|---|
| Founded | 1977 | 1923 |
| Country | Argentina | Denmark |
| Employees | N/A | 69500 |
| Industry | Integrated oil Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 206.0B | 208.2B |
| IPO Year | 1995 | N/A |
| Metric | YPF | NVO |
|---|---|---|
| Price | $49.17 | $47.21 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 3 | 11 |
| Target Price | $45.67 | ★ $51.00 |
| AVG Volume (30 Days) | 1.1M | ★ 10.6M |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 3.19% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.39 | N/A |
| Revenue Next Year | N/A | $3.70 |
| P/E Ratio | ★ N/A | $13.60 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.82 | $35.12 |
| 52 Week High | $57.49 | $64.16 |
| Indicator | YPF | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 48.80 | 41.94 |
| Support Level | $33.57 | $45.62 |
| Resistance Level | $56.82 | $46.92 |
| Average True Range (ATR) | 1.52 | 1.40 |
| MACD | -0.21 | -0.73 |
| Stochastic Oscillator | 20.64 | 25.13 |
YPF SA is an Argentina-based integrated oil and gas company. The company operates through four business segments: Upstream, Midstream and Downstream, LNG and Integrated Gas, and New Energies. The Upstream segment focuses on the exploration and production of crude oil and natural gas. The Midstream and Downstream segment includes refining, transportation, and commercialization of crude oil, refined, and petrochemical products. The LNG and Integrated Gas segment is involved in natural gas transportation, processing, storage, and commercialization. The New Energies segment focuses on energy transition initiatives, including natural gas distribution, power generation, renewable energy, and related technology development. It generates majority of revenue from Midstream and Downstream segment.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.